Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab-based perioperative combination therapy in resectable gastric or gastroesophageal junction adenocarcinoma
CTR20253061Phase 2Active
- Sponsor
- Chengdu Shengdi
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Chengdu Shengdi. Started Aug 2025; status: active.
02
Drugs
adebrelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20253061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253061.